Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 8:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Attention-Deficit/Hyperactivity Disorder (ADHD) Clear all
Completed Phase 4 Interventional Results available

Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD

NCT02096952
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder, Autism Spectrum Disorder
Interventions
Methylphenidate extended-release liquid formulation
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Jun 10, 2026, 8:02 AM EDT
Completed Phase 3 Interventional Results available

Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD

NCT00506285
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate Transdermal System (MTS), placebo patch
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Jun 10, 2026, 8:02 AM EDT
Completed Phase 3 Interventional Results available

Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD

NCT04143217
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
38
States / cities
Beverly Hills, California • Garden Grove, California • Los Alamitos, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Jun 10, 2026, 8:02 AM EDT
Withdrawn Not applicable Interventional

Mobile Health Solutions for Behavioral Skill Implementation Through Homework

NCT02662140
View directory record Official record
Conditions
Oppositional Defiant, Conduct Disorder
Interventions
Mobile Health Applictaion
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
7 Years to 11 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Jun 10, 2026, 8:02 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Network Control TMS fMRI

NCT05736458
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder, Working Memory
Interventions
Transcranial Magnetic Stimulation (TMS), High controllability TMS target
Device · Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 28 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Jun 10, 2026, 8:02 AM EDT
Completed Phase 4 Interventional

Effectiveness of ATMX in Treating Adolescents With ADHD and SUD

NCT00218322
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Substance-Related Disorders
Interventions
Atomoxetine hydrochloride, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
15 Years to 30 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Jun 10, 2026, 8:02 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder

NCT02478788
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
mixed amphetamine salts-extended release (MAS-XR), Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
10 Years to 18 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jun 10, 2026, 8:02 AM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia

NCT00856973
View directory record Official record
Conditions
Insomnia, Attention Deficit Hyperactivity Disorder
Interventions
eszopiclone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
73
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2013 · Synced Jun 10, 2026, 8:02 AM EDT
Completed Not applicable Interventional

Assessing Mobile Apps for Adult ADHD

NCT06256003
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
UC-A, UC-N
Device
Lead sponsor
Think Now Incorporated
Industry
Eligibility
18 Years to 50 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Berkeley, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Jun 10, 2026, 8:02 AM EDT
Completed Not applicable Interventional

Pediatric Aquatic Occupational Therapy for Children With Sensory Processing Challenges

NCT06484946
View directory record Official record
Conditions
Sensory Processing Disorder, Autism Spectrum Disorder, ADHD
Interventions
aquatic occupational therapy
Other
Lead sponsor
Kristen Pataki
Other
Eligibility
4 Years to 9 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Seven Hills, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Jun 10, 2026, 8:02 AM EDT
Completed No phase listed Observational Results available

The Parenting Young Children Check-up: Proof-of-Concept Trial

NCT04113304
View directory record Official record
Conditions
Disruptive Behavior Disorders
Interventions
Parenting Young Children Check-up (PYCC)
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 99 Years
Enrollment
6 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Jun 10, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI

NCT02225106
View directory record Official record
Conditions
Cognition Disorder, Attention Deficit Disorder, Traumatic Brain Injury
Interventions
Methylphenidate
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Jun 10, 2026, 8:02 AM EDT
Completed Not applicable Interventional Results available

Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study

NCT01533493
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Executive Function Deficits (EFD)
Interventions
Placebo, Memantine Hydrochloride, OROS-Methylphenidate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Jun 10, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Effects of Methylphenidate on Cellular Abnormalities in Children With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00409708
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy, Behavior Therapy
Drug · Behavioral
Lead sponsor
Novartis
Industry
Eligibility
6 Years to 12 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2011 · Synced Jun 10, 2026, 8:02 AM EDT
Terminated Phase 3 Interventional Results available

Intervention for Teens With ADHD and Substance Use

NCT02502799
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Brief Early Intervention, Parent Training with Adolescent Cognitive Behavioral Therapy, Methylphenidate
Behavioral · Drug
Lead sponsor
Florida International University
Other
Eligibility
12 Years to 16 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Jun 10, 2026, 8:02 AM EDT
Not listed Phase 1Phase 2 Interventional

Intervening Early With Neglected Children

NCT02093052
View directory record Official record
Conditions
Conduct Disorder, ADHD, Depression
Interventions
Attachment and Biobehavioral Catch-up, Developmental Education for Families
Behavioral
Lead sponsor
University of Delaware
Other
Eligibility
6 Years to 8 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2024
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Jun 10, 2026, 8:02 AM EDT
Completed Phase 4 Interventional

Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD

NCT00191048
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder, Comorbid Dyslexia
Interventions
Atomoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 16 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
8
States / cities
Rolling Hills Estate, California • Maitland, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2007 · Synced Jun 10, 2026, 8:02 AM EDT
Terminated Phase 4 Interventional Results available

Lisdexamfetamine's Effect In ADHD in the Brain and Cognition

NCT02170298
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Lisdexamfetamine
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
12 Years to 30 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 25, 2019 · Synced Jun 10, 2026, 8:02 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence

NCT00553319
View directory record Official record
Conditions
Adult Attention Deficit Hyperactivity Disorder, Cocaine Dependence
Interventions
Placebo, Adderall-XR
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Jun 10, 2026, 8:02 AM EDT
Completed Phase 4 Interventional Results available

Atomoxetine in Veterans With Comorbid ADHD/PTSD

NCT02287038
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine 80 MG
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
20 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Jun 10, 2026, 8:02 AM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00528697
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
ABT-089, atomoxetine, placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
6 Years to 12 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
20
States / cities
Little Rock, Arkansas • El Centro, California • Boulder, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Jun 10, 2026, 8:02 AM EDT
Completed Not applicable Interventional

Integrated Parent Training for Treating Depression in Mothers of Children With Attention Deficit Hyperactivity Disorder

NCT00316290
View directory record Official record
Conditions
Depression, Attention Deficit Disorder With Hyperactivity
Interventions
Integrated Parent Training, Behavioral Parent Training
Behavioral
Lead sponsor
University of Maryland, College Park
Other
Eligibility
6 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Jun 10, 2026, 8:02 AM EDT
Completed Not applicable Interventional

Does Active Parent Involvement in Deliberation and Choice Improve Medication Persistence for Their Child With ADHD

NCT00631280
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Choice, Recommendation
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 11 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Jun 10, 2026, 8:02 AM EDT
Recruiting Phase 4 Interventional

An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening

NCT06577779
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Methylphenidate Hydrochloride Extended Release Capsule
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jun 10, 2026, 8:02 AM EDT